Latest Industry Insights

For the world’s leading neuroscientists, unlocking the brain’s capacity to stimulate neural plasticity has become something of a Holy Grail. In this Insight, NervGen Pharma president and CEO Paul Brennan details why plasticity is so important for the brain.

In this interview, Jim Ross highlights several recent examples of how bioelectronic assays are helping to advance drug discovery for neurological diseases ranging from pediatric epilepsy to Burning Man Syndrome.

Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.

Unpicking our brain's complexity at a cellular level is a mammoth task. How do our genes, cells and electrical impulses come together to decode the world around us? At Boston University Assistant Professor Jerry Chen is trying to crack this code. In this interview, we speak to Chen about his study’s aims, findings and implications.

Technology Networks spoke to Atara’s chief medical officer, AJ Joshi, to learn more about ATA188 – an off-the-shelf, allogeneic T-cell immunotherapy – and how it could revolutionize treatment for MS patients.

Our ability to treat disorders of the body has advanced significantly in the 21st century. But that progress has not been matched by new therapies for psychiatric conditions. atai Life Sciences, a clinical-stage biopharmaceutical company, recently launched a new company that aims to correct that imbalance.

Technology Networks recently spoke with Jakob Dupont, head of global research & development at Atara Bio, to learn more about the company’s novel allogeneic EBV T-cell platform and discover how it’s enabling a differentiated approach to allogeneic cell therapy.

In this interview, we speak to Dr. Antal Szalay, CEO of Ultimate Medicine, about how his company helped establish that a microbiome metabolite can cause age-related memory loss.

Recent legislation changes by Health Canada have seen psychedelics become easier to prescribe for a range of mental health conditions. We spoke to Alexander Somjen, CEO of Origin Therapeutics, to find out what the impact of these changes will be for physicians, patients and providers.

Technology Networks spoke to Dr. Mark Kotter, CEO and founder of bit.bio to learn about opti-ox™ and the development, benefits and applications of ioSkeletal Myocytes.